BioLineRx Corp (BLRX): Price-to-Revenue Ratio

Brandmark of BioLineRx Corporation (BLRX)

BioLineRx Ltd. (BLRX) is betting on licensing its patented developments to pharma behemoths, which ensures high scalability. This P/S multiple chart visualizes the dynamics of this strategy, where 4.80 becomes the new value of the indicator. Growth is supported by Aphexda sales and oncology candidates, while the use of a CRO contractor network for clinical trials effectively reduces the company's operating expenses.

BLRX BioLineRx Ltd. P/S Multiple (03/28/2024 - 11/13/2026)

BioLineRx Corp (BLRX) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price biolinerx.com|BLRX - Price Target Chart
- stock exchange capitalization data:
Market Value BioLineRx Corp|BLRX - Total Company Value
- issuer book value statistics:
Net Asset Value per Share BioLineRx|BLRX - Book Capitalization|Market Value to Equity Ratio biolinerx.com|BLRX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital BioLineRx Ltd.|BLRX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital BioLineRx Corporation|BLRX - Company Total Debt|Debt to Book Capital BioLineRx Corp|BLRX - Company Long-Term Debts|Company Short-Term Loans and Borrowings BioLineRx|Immediate Liquidity biolinerx.com
- earnings and multiples data:
BLRX - Company Net Income|Expected Net Income BioLineRx Ltd.|BLRX - P/E Multiple|Forward P/E Multiple BioLineRx Ltd|BLRX - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio BioLineRx Corp|BLRX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months BioLineRx|BLRX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months biolinerx.com|BLRX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year BioLineRx Ltd.
- issuer revenue and sales details:
BLRX - Company Revenue|Company Expected Sales Volume biolinerx.com|BLRX - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio BioLineRx Corp
Summary company analytics:biolinerx.com
Mass-produced product of BioLineRx Corporation

BioLineRx Ltd. (BLRX) is scaling its business through the commercialization of innovative oncology drugs, including stem cell mobilization agents. The market capitalization-to-annual revenue ratio allows for tracking the asset's value dynamics relative to actual cash inflows. This metric measures the premium investors are willing to pay per unit of revenue amid inflationary pressures. An analysis of the price-to-sales valuation helps determine the degree of stock overvaluation relative to the issuer's operational successes.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Corp|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab Biopharma IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics Inc HRTX|Market Cap to Revenue NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Market Capitalization-to-Revenue Ratio|Corbus Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume CRDF (Cardiff Oncology Inc.)|BeyondSpring - P/S Multiple|Market Capitalization-to-Revenue Ratio BCAB (BioAtla, Inc.)|LIXT: P/S Multiple|Price to Sales Citius Pharmaceuticals, Inc. (CTXR)|Price-to-Revenue Ratio Cellectar Biosciences|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple kaziatherapeutics.com (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales cyclacel.com|GTHX: P/S Multiple|KRON (Kronos Bio Inc) - Price-to-Revenue Ratio|KTRA (Kintara) - P/S Multiple|Oncternal Corp (ONCT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Portage Biotech Inc. (PRTG)